Presentation is loading. Please wait.

Presentation is loading. Please wait.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Published byLydia Anthony Modified over 9 years ago

Similar presentations

Presentation on theme: "Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory."— Presentation transcript:

1 Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory Committee 27 February 2013

2 Inactivated Vaccine Serology Studies l Purpose: Evaluation of anti-HA antibodies from children, adults and older adults who had received current trivalent inactivated vaccines (2012-2013 formulation) l Serum samples: Five panels of sera from adults, 5 panels from elderly and 3 panels from pediatric populations were analyzed at 6 laboratories. Sera were collected 21-28 days post-vaccination. The most of the panels were pre-screened to avoid sera with low antibodies titer. l Methods: –Hemagglutination inhibition (HI) titers to recent isolates were compared to HI titer of the vaccine virus by HI assay –A subset of sera was tested by micro-neutralization assay 2

3 3 Serum panels used for studies: seasonal trivalent vaccine CHINACHILDREN (12-60M) ADULTS OLDER ADULTS A/Christchurch/16/2010 (H1N1pdm09) (NIB-74xp) A/Victoria/361/2011 (H3N2) (IVR-165) B/Hubei-Wujiagang/158/2009 (NYMC BX-39 JAPANADULTS OLDER ADULTS A/California/7/2009 (H1N1pdm09) (NYMC X-179A) A/Victoria/361/2011 (H3N2) (IVR-165) B/Wisconsin/1/2010 (NYMX BX-41) USA*CHILDREN (6-24M) ADULTS OLDER ADULTS A/California/7/2009 (H1N1pdm09) (NYMC X-179A) A/Victoria/361/2011 (H3N2) (IVR-165) B/Texas/6/2011 EUROPEADULTS OLDER ADULTS A/California/7/2009 (H1N1pdm09) (NYMC X-181) A/Victoria/361/2011 (H3N2) (IVR-165) B/Hubei-Wujiagang/158/2009 (NYMC BX-39 * two sets: one donated from a US manufacture and the other from US contract with CDC

4 4 A(H1N1)pdm09 Serology

5 Antigens for serology: VACCINE VIRUS A/California/7/2009 REPRESENTATIVE CURRENT VIRUSES A/Bangladesh/2021/2012 egg A/Gansu-Ganzhou/SWL33/2012 egg A/Gansu-Ganzhou/SWL33/2012 cell A/Stockholm/34/2012 cell A/Chiang Rai/312/2012 cell A/India/2192/2012 cell A/Washington/24/2012 egg 5

6 HI ANTIBODY RESPONSES TO THE A(H1N1)pdm09 COMPONENT (% GMT) Slide 6 summarizes average geometric mean (GMT) antibody titers of vaccine trials by hemagglutination inhibition (HI) test, indicating that A/California/7/09 antigen stimulated antibodies of similar titers to the vaccine and recent H1N1 viruses. 6 relative GMT

7 A(H1N1)pdm09-summary Vaccines containing A/California/7/2009 antigens induced anti-HA antibodies of similar geometric mean HI titers to the vaccine virus and the majority of representative A(H1N1)pdm09 viruses 7

8 8 A(H3N2) Serology

9 Antigens for Serology VACCINE VIRUS A/Victoria/361/2011 (egg or cell) REPRESENTATIVE CURRENT VIRUSES A/Attecoube/gr97/2012 cell -> egg A/Hawaii/22/2012 egg A/Hawaii/22/2012 cell A/Sapporo/125/2012cell A/Texas/50/2012 cell A/Texas/50/2012 egg A/Ohio/02/2012 cell A/Delaware/15/2012 cell A/South Carolina/16/2012cell A/Beijing-Xicheng/12423/2012 cell A/Fujian-Yanping/1394/2012 cell A/Singapore/22/2012 egg A/Yamaguchi/30/2012 cell 9

10 HI ANTIBODY RESPONSES TO THE A(H3N2) COMPONENT –Example: Paediatric Trial No. of Sera Virus strain pre- vacc GMT Post-vacc GMT %Post GMT Vs Egg-virus %Post GMT Vs Cell-virus US 20A/Victoria/361/2009 Egg22160100 A/Victoria/361/2009 Cell625100 A/Texas/50/2011 Cell63522140 A/Hawaii/22/2012 Cell82918116 A/Beijing-Xicheng/12423/2012 Cell613852 A/Delaware/15/2012 Cell514956 A/South Carolina/16/201263220128 China 20A/Victoria/361/2009 Egg88292100 A/Victoria/361/2009 Cell2553100 A/Texas/50/2011 Cell378630162 A/Hawaii/22/2012 Cell408027151 A/Beijing-Xicheng/12423/2012 Cell20451585 A/Delaware/15/2012 Cell1426949 A/South Carolina/16/2012287525141 Data from CDC 10

11 HI ANTIBODY RESPONSES TO THE A(H3N2) COMPONENT: using A/Victoria/361/2011 egg- grown virus as reference relative GMT Egg-grown ref. All cell grown Cell-grown A/Vic 11 Slide 11 summarizes average GMT titers of vaccine trials by HI test, indicating that vaccines containing A/Victoria/361/2011 antigens induced anti-HA antibodies of reduced geometric mean HI titers to the majority of recent cell-propagated A(H3N2) viruses, including cell- propagated A/Victoria/361/2011 virus.

12 HI ANTIBODY RESPONSES TO THE A(H3N2) COMPONENT: using A/Victoria/361/2011 cell- grown virus as reference relative GMT Cell-grown ref. All cell grown 12 Slide 12 shows the results from the same vaccine trials in slide 11, but the cell-propagated A/Victoria/361 was used as the reference antigen. There were no significant GMT differences between the recent cell- propagated A(H3N2) viruses and cell-propagated A/Victoria/361/2011 virus, indicating that cell-propagated A/Victoria/361/2011 virus and the recent cell-propagated A(H3N2) viruses were antigenically indistinguishable in HI test.

13 Elderly Population % GMT HI ANTIBODY RESPONSES TO THE A(H3N2) COMPONENT: microneutralisation assays using A/Victoria/361/2011 cell-grown virus as reference HI ANTIBODY RESPONSES TO THE A(H3N2) COMPONENT: microneutralisation assays using A/Victoria/361/2011 cell-grown virus as reference US JAPAN UK 13 Slide 13 shows the example of antibody responses of vaccine trials by micro-neutralisation test. There were no significant GMT differences between the recent cell-propagated A(H3N2) viruses and cell-propagated A/Victoria/361/2011 virus, indicating that cell-propagated A/Victoria/361/2011 virus and the recent cell-propagated A(H3N2) viruses were antigenically indistinguishable in micro-neutralisation test. Cell-grown A/Vic. ref. egg-grown A/Vic

14 A(H3N2)-summary Vaccines containing A/Victoria/361/2011 antigens induced anti-HA antibodies of reduced geometric mean HI titers to the majority of recent cell- propagated A(H3N2) viruses compared to the egg- propagated vaccine viruses. 14

15 Influenza B Serology 15

16 Antigens for Serology VACCINE VIRUS (Yamagata-clade 3) B/Wisconsin/1/2010, B/Hubei-Wujiagang/158/2009 or B/Texas/6/2010 REPRESENTATIVE CURRENT VIRUSES Yamagata lineage B/Hyogo/4002/2012 (clade 3)cell B/Heilongjiang-Jiguan/1409/2012 (clade 3)cell B/England/580/2012 (clade 2)cell B/Massachusetts/02/2012 (clade 2)egg B/Massachusetts/02/2012 (clade 2)cell B/New Mexico/04/2012 (clade 2)cell B/Brisbane/36/2012 (clade 2)egg Victoria lineage B/Brisbane/60/2008 egg B/Jiangsu-Tianning/1666/2012 egg B/Jiangsu-Pingjiang/1494/2012cell B/South Australia/36/2012egg 16

17 HI ANTIBODY RESPONSES TO THE B COMPONENT Assays with significant reduction (≥ 50 %) in GMT clade 2 vs clade 3 viruses expected ratio: 5:3 observed ratio: 5:1 18

18 B-summary Vaccines containing B/Wisconsin/1/2010-like antigens generally induced anti-HA antibodies of similar geometric mean HI titers to vaccine virus and the majority of recent B/Yamagata/16/88 lineage viruses. However, significant reductions in GMT were observed more frequently for some serum panels when testing clade 2 virus as compared to clad 3 viruses. 19

19 Human Serology Studies-Summary l H1N1pdm09 –Sera from recipients of vaccine containing A/California/7/2009 antigen reacted well with the majority of representative recent A(H1N1)pdm09 viruses. l H3N2 –Sera from recipients of vaccine containing egg-grown A/Victoria/361/2011 antigen reacted less well with representative recent cell-propagated A(H3N2) viruses. l B – B/YAMAGATA/16/88-lineage Sera from recipients of vaccine containing B/Wisconsin/1/2010-like antigen generally reacted well with the majority of representative recent Yamagata lineage viruses, but significant reductions in GMT were more frequent for clade 2 viruses than for clade 3 viruses. – B/VICTORIA/2/87-lineage Sera from recipients of vaccine containing B/Yamagata/16/88-lineage antigen reacted less well to recent B/Victoria/2/87-lineage viruses. 20

Download ppt "Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory."

Similar presentations

Candidate Vaccine Strains and Potency Reagents for Influenza Season

Candidate Vaccine Strains and Potency Reagents for Influenza Season
Duration of Serum Antibody Response to Seasonal Influenza Vaccines: Summary The level of antibody response made to seasonal influenza vaccines depends.

Duration of Serum Antibody Response to Seasonal Influenza Vaccines: Summary The level of antibody response made to seasonal influenza vaccines depends.
Vaccines and Related Biological Products Advisory Committee 18 February 2009 Topic 2: Considerations and Implications for adding two B Strains to the Seasonal.

Vaccines and Related Biological Products Advisory Committee 18 February 2009 Topic 2: Considerations and Implications for adding two B Strains to the Seasonal.
INFORMATION FOR THE VACCINE AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER, FDA (Seasonal Influenza and Zoonotic Influenza) FEBRUARY 28, 2012.

INFORMATION FOR THE VACCINE AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER, FDA (Seasonal Influenza and Zoonotic Influenza) FEBRUARY 28, 2012.
Avian and Pandemic Influenza Vaccine Development John Treanor Professor of Medicine University of Rochester Medical Center Rochester, NY.

Avian and Pandemic Influenza Vaccine Development John Treanor Professor of Medicine University of Rochester Medical Center Rochester, NY.
Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.
Lisa Grohskopf, MD, MPH Medical Officer Influenza Division Centers for Disease Control and Prevention U.S. Influenza Surveillance National Center for Immunization.

Lisa Grohskopf, MD, MPH Medical Officer Influenza Division Centers for Disease Control and Prevention U.S. Influenza Surveillance National Center for Immunization.
Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.
Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
National Vaccine Advisory Committee November 29, 2005 Update on NIH H5N1 Vaccine Trials Linda C. Lambert Chief, Respiratory Diseases Branch Division of.

National Vaccine Advisory Committee November 29, 2005 Update on NIH H5N1 Vaccine Trials Linda C. Lambert Chief, Respiratory Diseases Branch Division of.
Influenza Vaccine Responses Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Influenza Vaccine Responses Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.
Influenza Vaccine Manufacturing Industry perspective for 2013-2014 influenza vaccine supply VRBPAC, 27 February 2013 The FDA CBER requested this annual.

Influenza Vaccine Manufacturing Industry perspective for influenza vaccine supply VRBPAC, 27 February 2013 The FDA CBER requested this annual.
Influenza Timothy Wiemken, PhD MPH CIC Assistant Professor Division of Infectious Diseases University of Louisville

Influenza Timothy Wiemken, PhD MPH CIC Assistant Professor Division of Infectious Diseases University of Louisville
Influenza Virus Vaccine 2013-2014 Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.
Influenza Virus Vaccine 2014-2015 Strain Selection Vaccines and Related Biological Products Advisory Committee (2/28/2014) Jerry P. Weir, Ph.D., Director.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/28/2014) Jerry P. Weir, Ph.D., Director.
INFLUENZA VACCINE Group 1 Zainab Ashfaq Bushra Abbas Ahtasham Danish.

INFLUENZA VACCINE Group 1 Zainab Ashfaq Bushra Abbas Ahtasham Danish.
Influenza Vaccine Manufacturing Industry perspective for 2012-2013 influenza vaccine supply VRBPAC, 28 February 2012 The FDA CBER requested this annual.

Influenza Vaccine Manufacturing Industry perspective for influenza vaccine supply VRBPAC, 28 February 2012 The FDA CBER requested this annual.
INTRODUCTION TO INFLUENZA The (Ferret) Sneeze Heard Around The World: The Case Of The Bioengineered Bird Flu Case Study for AAC&U STIRS Project Jill M.

INTRODUCTION TO INFLUENZA The (Ferret) Sneeze Heard Around The World: The Case Of The Bioengineered Bird Flu Case Study for AAC&U STIRS Project Jill M.
INFORMATION FOR THE VACCINE AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER, FDA FEBRUARY 22, 2010 Nancy J. Cox, Ph. D Director WHO COLLABORATING.

INFORMATION FOR THE VACCINE AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER, FDA FEBRUARY 22, 2010 Nancy J. Cox, Ph. D Director WHO COLLABORATING.

Similar presentations

Ads by Google